Ultrasound-guided nerve hydrodissection for diabetic leg nerves

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study compares a real nerve hydrodissection procedure to a sham control in adults with diabetic leg nerve entrapment. Participants will undergo four in-person visits over about one month, with clinicians evaluating nerve function and quality of life. The study uses ultrasound guidance to inject around a compressed nerve and a sham procedure as a control, with patients and outcome assessors blinded to group assignment. The main outcomes include nerve function as measured by the Toronto Clinical Scoring System and changes in pain and daily living. The trial aims to determine whether this targeted injection can provide meaningful symptom relief for diabetic peripheral neuropathy with entrapment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 18-85 years, male or female;
2. Diagnosis of DLLEN meeting the following criteria: ① Clinical diagnosis of DPN (presence of DPN clinical symptoms plus at least one positive physical sign, or absence of symptoms but presence of two or more positive physical signs), with other etiologies excluded; ② Presence of unilateral or bilateral lower limb symptoms suggestive of peripheral nerve entrapment, including hypoesthesia/paresthesia in a specific nerve distribution area, pain and/or motor dysfunction, or a positive Tinel sign at the corresponding site; ③ Physical examination findings such as decreased or absent skin sensation in the corresponding nerve distribution area, reduced or absent strength of ankle dorsiflexion or eversion, metatarsophalangeal joint movement disorder, foot drop, or foot inversion; ④ Electrophysiological study showing slowing or blockade of nerve conduction velocity at a specific site (across a narrowed segment); ⑤ Imaging study (nerve ultrasound) showing compression of the corresponding nerve (cross-sectional area at the entrapment site exceeding the upper limit of the reference range, decreased nerve echogenicity, or swelling of the nerve fascicles). Diagnosis requires fulfillment of ①, ②, and ③, plus either ④ or ⑤;
3. Inadequate response to adequate treatment with medications such as mecobalamin and α-lipoic acid;
4. Understanding of the entire study process and voluntary provision of written informed consent.

Exclusion Criteria:

1. Presence of another clearly identified etiology assessed by the investigator as the primary cause of the patient's current lower limb neurological symptoms, including but not limited to: cervical or lumbar spine disease (e.g., radicular symptoms or sciatica), lower extremity vascular disease, cerebral infarction, thyroid dysfunction, vitamin B12 deficiency, heavy alcohol use history, recent chemotherapy or radiotherapy, drug toxicity, or other non-diabetic causes of neuropathy (e.g., CIDP, cauda equina syndrome, subacute combined degeneration of the spinal cord, Guillain-Barré syndrome);
2. Concurrent malignancy, active systemic infection, or immune system disease;
3. Lower limb edema due to any cause;
4. Skin breakdown or infection at the treatment site below the knee;
5. Severe cardiac, hepatic, or renal insufficiency (eGFR \<30 mL/min/1.73m², liver transaminases \>2.5 times the upper limit of normal, or New York Heart Association functional class ≥II);
6. Cognitive impairment or severe mental illness;
7. Pregnancy or breastfeeding;
8. Participation in another interventional clinical trial within the past 3 months;
9. Poor compliance, assessed as unlikely to complete the study per protocol;
10. Any other condition assessed by the investigator as making the patient unsuitable to complete the trial.

Where it's running

• The First Affiliated Hospital of Chongqing Medical University
  Chongqing, Chongqing Municipality, China Recruiting

Study contacts

• Study coordinator: Qingfeng Cheng, PhD
• Email: cqf19760516@163.com
• Phone: 13628482293

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Effects of perturbation-based balance training vs conventional balance training for reactive stepping in adults with diabetic nerve damage

  A 40-person study will test whether adding perturbation-based balance training helps adults with diabetic peripheral neuropathy react better to balance threats compared with standard balance training.

  Recruiting Lahore University of Biological and Applied Sciences · Lahore, Punjab Province · NCT07902297

• Shortwave therapy for diabetic peripheral neuropathy

  A one-center study will test whether shortwave therapy given for five days can improve nerve symptoms in adults with diabetic neuropathy compared to a sham treatment.

  Recruiting Chongqing Medical University · Chongqing · NCT07625007

• MinION sequencing to identify microbes in diabetic foot bone infections

  This study will test a rapid MinION DNA sequencing method to identify bacteria, fungi, and resistance genes in infected diabetic foot wounds and compare the results with standard culture.

  Recruiting Centre Hospitalier Universitaire de Nīmes · Nîmes, Gard · NCT07391995

• Intraneural Facilitation and Otago Exercise for Diabetic Peripheral Neuropathy

  This study will test whether intraneural facilitation, the Otago exercise program, or a combination of both can improve balance, reduce neuropathic pain, and improve quality of life for people aged 50–75 with diabetic peripheral neuropathy.

  Recruiting Riphah International University · Lahore, Punjab Province · NCT07274735

• Topical Capsadyn (palmitated capsaicin) for diabetic neuropathic foot pain

  This study will test whether a topical Capsadyn cream can reduce foot pain in adults with diabetic peripheral neuropathy.

  Recruiting Early Phase 1 Carilion Clinic · Roanoke, Virginia · NCT07260656

• Melatonin for people with diabetic peripheral neuropathy

  This trial will test whether adding melatonin to usual care helps adults with type 2 diabetes who have peripheral neuropathy by reducing oxidative stress, lowering inflammation, and improving symptoms.

  Recruiting Phase 2 Ain Shams University · Cairo · NCT07036796

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.